Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
Consensus guidelines for asthma therapy
Contenu en anglais
Résumé
This article provides information on the consensus reached by the Antileukotriene Working Group on the role of leukotriene (LT) modifiers in the treatment of asthma.
Relevant and appropriate controlled clinical studies were used. Only literature in the English language was reviewed.
Material was taken from academic/scholarly journals and appropriate reviews.
Only limited use of LT-modifying agents has been recommended in recently published guidelines of the National Asthma Education and Prevention Program and the National Heart, Lung, and Blood Institute. Consequently, the Antileukotriene Working Group was convened to arrive at a consensus on the wider use of LT modifiers in the treatment of asthma. The group' s purpose was 2-fold: to review and disseminate information on the role of LT modifiers in clinical practice. As determined by the group, a thorough understanding of the patient's disease, patient education, and an effective patient-clinician relationship are key elements in overall patient management.
Based on evidence from clinical trials and expert opinions of participants comprising the Antileukotriene Working Group, LT-modifying agents potentially may be used as first-line therapy, in combination regimens, and as an alternative to inhaled corticosteroids in the treatment of asthma.
Source et droits
Publiée par Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2001. La recommandation elle-même se trouve à la source indiquée ici.
Prognia résume cette recommandation à des fins de consultation et d’enseignement. Il ne s’agit pas d’un avis médical. Vérifiez toujours la recommandation officielle et les protocoles locaux en vigueur avant de l’appliquer.
